HRT and breast cancer: Impact on population risk and incidence
HRT and breast cancer: Impact on population risk and incidence
复制标题
DOI：
10.1016/j.ejca.2005.03.030
复制
发表时间：
2005-08-01
影响因子：
8.4
通讯作者：
Boyages, J
中科院分区：
文献类型：
--
作者：
Coombes, NJ;Taylor, R;Boyages, J
这项研究计算了激素替代疗法 (HRT) 对澳大利亚乳腺癌发病率的潜在影响，并估计了女性 HRT 处方的变化如何影响这种风险。 HRT 对乳腺癌发病率的影响是使用归因分数技术和来自 2001 年澳大利亚健康调查的患病率数据以及公布的 HRT 使用带来的乳腺癌相对风险率来估计的。在澳大利亚，12% 的成年女性目前正在使用 HRT，2001 年报告了 11,783 例乳腺癌。其中，1066 (9%) 可能归因于 HRT。限制 65 岁以下女性的 HRT 使用、10 年后停止 HRT 处方或将雌激素和黄体酮联合 HRT 限制为 5 年（但将处方水平保持在 2001 年的水平）可能会分别减少每年乳腺癌病例数 280 (2.4%)、555 (4.7%) 或 674 (5.7%)。总之，本研究证明，当HRT流行率相对较高时，对人群中乳腺癌发病率的影响将是显着的。 HRT 处方做法的微小修改可能会影响澳大利亚乳腺癌的发病率，并产生相关的财务和医疗保健供应影响。 (C) 2005 Elsevier Ltd. 保留所有权利。
This study has calculated the potential impact of hormone replacement therapy (HRT) on breast cancer incidence in Australia and has estimated how changes in prescribing HRT to women could affect this risk. The effects of HRT on breast cancer incidence was estimated using the attributable fraction technique with prevalence data derived from the 2001 Australian Health Survey and published rates of breast cancer relative risks from HRT use. In Australia, 12% of adult women were current HRT users and in 2001, 11783 breast cancers were reported. Of these, 1066 (9%) were potentially attributable to HRT. Restricting HRT use to women aged less than 65 years, ceasing HRT prescribing after 10 years or limiting combined oestrogen and progesterone HRT to five years (but otherwise keeping prescription levels to 2001 levels) may reduce the annual breast cancer caseload by 280 (2.4%), 555 (4.7%) or 674 (5.7%), respectively. In conclusion, this study has demonstrated that when HRT prevalence is relatively high, the effect on breast cancer incidence in the population will be significant. A small modification in HRT prescribing practices may impact breast cancer incidence in Australia with associated financial and health care provision implications. (C) 2005 Elsevier Ltd. All rights reserved.